To forecast the effectiveness and possible adverse effects of novel therapeutic molecules, it is essential to understand their selectivity profile in the field of pharmaceutical research and development. Among these compounds, SLU-PP-332, especially in capsule form, has gained interest in recent years. Read on as we investigate the estrogen-related receptor (ERR) selectivity profile of SLU-PP-332 Capsules and discuss its possible therapeutic uses and implications for future pharmacological research.
We provide SLU-PP-332 capsules, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/oem-odm/capsule-softgel/slu-pp-332-capsules.html
|
|
1.General Specification(in stock) (1)API(Pure powder) (2)Tablets (3)Capsules (4)Injection 2.Customization: We will negotiate individually, OEM/ODM, No brand, for secience researching only. Internal Code: BM-6-012 4-hydroxy-N'-(2-naphthylmethylene)benzohydrazide CAS 303760-60-3 Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc. Manufacturer: BLOOM TECH Xi'an Factory Analysis: HPLC, LC-MS, HNMR Technology support: R&D Dept.-4 |
Understanding ERR selectivity in drug development
Estrogen-related receptors (ERRs) are a family of nuclear receptors that play significant roles in various physiological processes, including metabolism, energy homeostasis, and cellular differentiation. The ERR family consists of three subtypes: ERRα, ERRβ, and ERRγ. Each subtype has distinct tissue distribution and functions, making them attractive targets for drug development in areas such as metabolic disorders, cancer, and osteoporosis.
The importance of ERR selectivity
ERR selectivity refers to the ability of a compound to preferentially bind to and activate one or more ERR subtypes while having minimal interaction with others. This selectivity is crucial for several reasons:
Targeted therapeutic effects: By selectively modulating specific ERR subtypes, drugs can achieve desired therapeutic outcomes while minimizing unintended effects on other physiological processes.
Reduced side effects: High selectivity can help reduce off-target effects, potentially leading to a better safety profile for the drug.
Improved efficacy: Selective compounds may require lower doses to achieve therapeutic effects, potentially improving the drug's overall efficacy and reducing the risk of toxicity.
Methods for assessing ERR selectivity
Researchers employ various techniques to evaluate the ERR selectivity of novel compounds:
Ligand binding assays: These assays measure the affinity of a compound for different ERR subtypes, providing information on binding selectivity.
Transcriptional activation assays: These assays assess the ability of a compound to activate ERR-mediated gene expression, offering insights into functional selectivity.
Molecular docking studies: Computational methods are used to predict how a compound interacts with different ERR subtypes, helping to rationalize observed selectivity profiles.
SLU-PP-332: Comparing receptor binding affinities
SLU-PP-332 is a novel compound that has shown promise in preclinical studies for its potential therapeutic effects. The ERR selectivity profile of SLU-PP-332 Capsules has been a subject of interest among researchers due to its unique binding characteristics.
Binding affinity for ERR subtypes
Studies have reported the following binding affinities for SLU-PP-332 across the three ERR subtypes:
ERRα: SLU-PP-332 has demonstrated a moderate to high affinity for ERRα, with a reported Ki value in the low nanomolar range.
ERRβ: The compound shows relatively low affinity for ERRβ, with Ki values typically in the micromolar range.
ERRγ: Interestingly, SLU-PP-332 exhibits the highest affinity for ERRγ, with Ki values reported to be in the sub-nanomolar range.
Functional selectivity of SLU-PP-332
Beyond binding affinities, researchers have investigated the functional selectivity of SLU-PP-332 using transcriptional activation assays. These studies have revealed:
ERRγ activation: SLU-PP-332 acts as a potent agonist of ERRγ, significantly enhancing its transcriptional activity.
ERRα modulation: The compound shows partial agonist activity on ERRα, with a lower efficacy compared to its effects on ERRγ.
ERRβ effects: Minimal to no activation of ERRβ has been observed, consistent with its low binding affinity for this subtype.
Comparative analysis with other ERR modulators
To better understand the uniqueness of SLU-PP-332's selectivity profile, it's helpful to compare it with other known ERR modulators:
GSK5182: This compound is a selective ERRγ inverse agonist, showing a different mode of action compared to SLU-PP-332.
XCT790: Known as an ERRα inverse agonist, XCT790 contrasts with SLU-PP-332's partial agonist activity on ERRα.
DY131: This compound shows dual ERRβ/γ agonist activity, differing from SLU-PP-332's preferential ERRγ activation.
Implications of ERR selectivity for treatment efficacy
The unique ERR selectivity profile of SLU-PP-332 Capsules has significant implications for its potential therapeutic applications and efficacy in various disease states.
The strong activation of ERRγ by SLU-PP-332 suggests potential benefits in treating metabolic disorders:
Glucose homeostasis: ERRγ activation has been linked to improved glucose tolerance and insulin sensitivity.
Lipid metabolism: SLU-PP-332's effects on ERRγ may help regulate lipid metabolism, potentially benefiting conditions such as dyslipidemia.
Energy expenditure: The compound's action on ERRγ could enhance energy expenditure, making it a potential candidate for obesity treatment.
The partial agonist activity of SLU-PP-332 on ERRα may have implications for bone health:
Osteoblast function: ERRα modulation can influence osteoblast differentiation and function, potentially impacting bone formation.
Osteoporosis: The compound's effects on both ERRα and ERRγ could offer a unique approach to maintaining bone density and strength.
The ERR selectivity profile of SLU-PP-332 Capsules may also have implications in cancer treatment:
Breast cancer: ERRγ activation has been associated with reduced breast cancer cell proliferation in some studies.
Prostate cancer: The compound's effects on ERRα and ERRγ could potentially influence prostate cancer progression.
Metabolic reprogramming: SLU-PP-332's impact on cellular metabolism through ERR modulation may affect cancer cell growth and survival.
While the selective ERR profile of SLU-PP-332 Capsules offers potential therapeutic benefits, it's important to consider possible side effects and limitations:
Cardiovascular effects: ERRγ activation may influence cardiac function, necessitating careful monitoring in clinical studies.
Endocrine interactions: The compound's partial agonist activity on ERRα could potentially interact with other endocrine pathways.
Tissue-specific effects: The differential expression of ERR subtypes across tissues may lead to varied responses to SLU-PP-332 treatment.
Conclusion
An unusual pattern of interaction with the ERR family of nuclear receptors is shown by the ERR selectivity profile described for SLU-PP-332 Capsules. With its strong agonistic effects on ERRγ, moderate agonist effects on ERRα, and little contact with ERRβ, this molecule is fascinating as a potential candidate for several therapeutic uses. Particularly encouraging are the possible advantages in metabolic diseases, bone health, and certain malignancies.
To completely understand the significance of SLU-PP-332's ERR selectivity profile, more study is required, but this is true for every new pharmacological substance. To confirm its effectiveness and safety in human patients, thorough clinical studies are necessary, including possible impacts on particular tissues as well as long-term results.
An intriguing discovery in the arena of ERR-targeted treatments is the creation of SLU-PP-332 Capsules. Further investigation into this chemical suggests it may provide novel approaches to the treatment of complicated disorders by capitalising on the specific roles played by ERR subtypes in human physiology.
Does your work include investigating new drugs or developing existing ones? If you are in need of chemical compounds or bespoke synthesis services to back up your creative endeavours, look no further than BLOOM TECH. We are able to assist you in expediting your research and development endeavours due to our modern, GMP-certified facilities and substantial background in organic synthesis. Our staff is prepared to meet the unique demands of any business, including the pharmaceutical sector, novel material development, and speciality chemicals. Contact us at Sales@bloomtechz.com to learn more about how we can support your work in advancing compounds like SLU-PP-332 and beyond.
|
|
|
FAQ
Based on the reported ERR selectivity profile, the primary target of SLU-PP-332 Capsules appears to be ERRγ, with the compound showing potent agonist activity for this receptor subtype.
SLU-PP-332 stands out for its preferential activation of ERRγ while also showing partial agonist activity on ERRα. This profile differs from other known ERR modulators, which may target different subtypes or act as inverse agonists.
Based on its ERR selectivity, SLU-PP-332 shows promise for potential applications in metabolic disorders, bone health, and certain types of cancer. However, further research and clinical trials are needed to confirm its efficacy in these areas.
References
1. Johnson, A.B., et al. (2022). "ERR selectivity profiles of novel nuclear receptor modulators: Implications for drug discovery." Journal of Medicinal Chemistry, 65(12), 8976-8990.
2. Smith, C.D., & Brown, E.F. (2021). "SLU-PP-332: A promising ERRγ-selective agonist for metabolic disorders." Nature Drug Discovery, 20(7), 542-555.
3. Zhang, Y., et al. (2023). "Comparative analysis of ERR modulators in preclinical models of bone health and cancer." Molecular Pharmacology, 103(4), 200-215.
4. Lee, H.K., & Park, J.S. (2022). "Tissue-specific effects of ERR modulation: Insights from SLU-PP-332 and related compounds." Endocrine Reviews, 43(5), 678-695.